Three Approaches to Accessing the Japanese Market
An informative article in ASCPT’s Clinical and Translational Science from NOVARTIS was recently published, analyzing three approaches to accessing the Japanese market: the Japanese Phase I waiver, the first-in-human study conducted in Japan, and multifunctional Japanese Phase I studies.
Further analysis of cycle times emphasizes Japan’s globally competitive timelines, as “a key location for first-in-human and early phase trials.”
For those interested in learning more on these approaches, this is a worthwhile read!
-
Three Approaches to Accessing the Japanese Market
-
PMDA Symposium RE: Phase 1 Trial Inclusion Guidance
-
DIA Global Annual Meeting – Washington D.C.
-
IRB Schedule Update (2025~2026)
-
WORLD VACCINE CONGRESS 2025 – WASHINGTON, D.C.
-
JSCPT CONFERENCE – SAITAMA
-
TIDES EUROPE CONFERENCE – HAMBURG
-
FESTIVAL OF BIOLOGICS CONFERENCE – BASEL
-
IRB Schedule Update (2024~2025)
-
JOIN US IN San Diego – DIA 2024